Nimenrix® (Meningococcal group ACW₁₃₅Y conjugate vaccine)
What is Nimenrix and what is it used for?
Nimenrix is a conjugate vaccine that helps to provide protection against invasive disease caused by the bacteria Neisseria meningitidis types A, C, W-135 and Y. Invasive disease occurs when there is systemic spread of bacterium throughout the body causing serious infections such as septicaemia (blood infection) and meningitis (infection of the membranes around the brain and spinal cord).
Nimenrix may be given to adults, adolescents, children and infants over the age of 6 weeks.
Nimenrix will only protect against infections caused by the bacteria Neisseria meningitidis types A, C, W-135 and Y. As with all vaccines, Nimenrix may not protect everyone who is fully vaccinated.
When should the vaccine be administered?
Nimenrix is indicated for active immunisation of individuals from the age of 6 weeks and should be used in accordance with official available recommendations.
The medicine can only be obtained with a prescription.
The European Medicines Agency (EMA) is a decentralised agency of the European Union (EU), located in Amsterdam, the Netherlands. The Agency is responsible for the scientific evaluation, supervision and safety monitoring of medicines developed by pharmaceutical companies for use in the EU. See what guidance they offer about Nimenrix.
Medicines in Northern Ireland fall under the remit of the European Medicines Agency (EMA) whilst medicines in Great Britain (England, Scotland and Wales) fall under the remit of the Medicines and Healthcare products Regulatory Agency (MHRA) following the UK leaving the European Union. These agencies are responsible for the scientific evaluation, supervision and safety monitoring of medicines developed by pharmaceutical companies.
If you would like to see the Summary of Product Characteristics (SPC) or Patient Information Leaflet (PIL) for Nimenrix please follow these links:
Nimenrix (Meningococcal group ACW₁₃₅Y conjugate vaccine)
PP-NIM-GBR-0302 / October 2021